These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38321333)

  • 1. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.
    Badulescu S; Le GH; Wong S; Kwan ATH; Guo Z; Teopiz KM; Phan L; Subramaniapillai M; Rosenblat JD; Mansur RB; McIntyre RS
    Neurol Sci; 2024 Apr; 45(4):1335-1342. PubMed ID: 38321333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
    Teopiz KM; Kwan ATH; Le GH; Guo Z; Badulescu S; Ceban F; Meshkat S; Di Vincenzo JD; d'Andrea G; Cao B; Ho R; Rhee TG; Dev DA; Phan L; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
    Curr Med Res Opin; 2024 Jul; 40(7):1203-1209. PubMed ID: 38860901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a
    Liao S; Teopiz KM; Kwan ATH; Le GH; Wong S; Ballum H; Rhee TG; Badulescu S; Cao B; Guo Z; Meshkat S; Phan L; Subramaniapillai M; Ho R; McIntyre RS
    Curr Med Res Opin; 2024 Aug; 40(8):1407-1411. PubMed ID: 38954402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
    McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
    Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis.
    Le GH; Kwan ATH; Guo Z; Teopiz KM; Wong S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Badulescu S; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
    Psychiatry Res; 2024 Sep; 339():116068. PubMed ID: 38954891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.
    Kwan ATH; Guo Z; Ceban F; Le GH; Wong S; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; d'Andrea G; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
    Adv Ther; 2024 May; 41(5):1983-1994. PubMed ID: 38520501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis.
    Kleine N; Kwan ATH; Le GH; Guo Z; Phan L; Subramaniapillai M; McIntyre RS
    CNS Spectr; 2024 Apr; 29(2):150-154. PubMed ID: 38453677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater Role of Cognitive Impairment Over Fatigue in Post-COVID-19 Quality of Life: A Post-Hoc Analysis of a Randomized Controlled Trial.
    Kwan ATH; Lakhani M; Le GH; Singh G; Teopiz KM; Guo Z; Ceban F; Dhaliwal KK; Badulescu S; Ho R; Rhee TG; Cao B; d'Andrea G; McIntyre RS
    medRxiv; 2024 Mar; ():. PubMed ID: 38562760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.
    Le GH; Kwan ATH; Guo Z; Wong S; Badulescu S; Gill H; Teopiz KM; Meshkat S; Ceban F; Phan L; Subramaniapillai M; Di Vincenzo JD; Rosenblat JD; Mansur RB; d'Andrea G; Ho R; Rhee TG; McIntyre RS
    Acta Neuropsychiatr; 2024 Aug; 36(4):211-217. PubMed ID: 38605630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.
    Guttuso T; Zhu J; Wilding GE
    JAMA Netw Open; 2024 Oct; 7(10):e2436874. PubMed ID: 39356507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.
    Le GH; Kwan ATH; Wong S; Guo Z; Teopiz KM; Badulescu S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
    Adv Ther; 2024 Feb; 41(2):686-695. PubMed ID: 38114867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
    Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
    Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
    Florea I; Loft H; Danchenko N; Rive B; Brignone M; Merikle E; Jacobsen PL; Sheehan DV
    Brain Behav; 2017 Mar; 7(3):e00622. PubMed ID: 28293465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
    Kwan ATH; Le GH; Guo Z; Ceban F; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
    Ann Gen Psychiatry; 2024 Feb; 23(1):10. PubMed ID: 38424537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder.
    McIntyre RS; Loft H; Christensen MC
    Neuropsychiatr Dis Treat; 2021; 17():575-585. PubMed ID: 33654400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
    Papalexi E; Galanopoulos A; Kontis D; Markopoulou M; Balta G; Karavelas E; Panagiotidis P; Vlachos T; Ettrup A
    BMC Psychiatry; 2022 Aug; 22(1):548. PubMed ID: 35962369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
    Christensen MC; Loft H; Florea I; McIntyre RS
    CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.